| Literature DB >> 26553673 |
Laurence Cibrelus1, Clément Lingani2, Katya Fernandez1, Mamoudou H Djingarey2, William A Perea1, Stéphane Hugonnet1.
Abstract
BACKGROUND: A group A meningococcal (MenA) conjugate vaccine has progressively been introduced in the African meningitis belt since 2010. A country-wide risk assessment tool, the District Prioritization Tool (DPT), was developed to help national stakeholders combine existing data and local expertise to define priority geographical areas where mass vaccination campaigns should be conducted.Entities:
Keywords: PsA-TT; meningococcal meningitis; risk assessment; sub-Saharan Africa; vaccine introduction
Mesh:
Substances:
Year: 2015 PMID: 26553673 PMCID: PMC4639508 DOI: 10.1093/cid/civ671
Source DB: PubMed Journal: Clin Infect Dis ISSN: 1058-4838 Impact factor: 9.079
Figure 1.Summary of quantitative phase of District Prioritization Tool evaluation. Abbreviations: ACC, ability to conduct the campaigns; CBR, case burden ratio; CIR, cumulative incidence ratio; ERI, epidemic risk index; IF, immunity front; , automatic computation; , semiautomatic computation (interpretation required).
Variables Used for Quantitative Risk Analysis and Attribution of Performance Flags With the District Prioritization Tool for Neisseria meningitidis Serogroup A Vaccination
| Denominators |
Number of districts in the country Number of regions Number of years of standardized surveillance (ie, study period) Population |
| Epidemiological risk |
Number of meningitis suspected casesa,b Yearly incidenceb Identification of NmAa Number of outbreaks due to NmA since standardized surveillancea,b Number of years since last NmA outbreakb Number of reactive immunization campaigns against NmA over the previous 3 years (using polysaccharide vaccine)b Average vaccine coverage reached after reactive immunization against NmA over the previous 3 yearsb |
| Case burden |
Total number of NmA cases prior to and after standardized surveillancea,b Proportion of total number of cases in the countrya,b |
| Performance flags |
Immunity front: existence of a border with a district already immunized with PsA-TTb Ability to conduct the campaign: Number of preventive mass immunization campaigns for other diseases than meningitis conducted in each district over the 3 previous years by the Ministry of Health and partners (eg, yellow fever, measles)b and average vaccine coverage reached per district after these campaignsb |
| Population information |
Total population Target population (70% of total population) Number of doses based on wastage rate Population densityb |
Abbreviations: NmA, Neisseria meningitidis group A; PsA-TT, group A meningococcal polysaccharide–tetanus toxoid conjugate vaccine.
a Per district per year over study period.
b Also presented in the district profiles for meningitis.
Values of District Prioritization Tool Risk Indicators and Corresponding Risk Scores
| Risk Indicator | Scale | |||||
|---|---|---|---|---|---|---|
| CBR (case burden ratio) | Value | <1 | 1–2.9 | 3–4.9 | 5–9.9 | ≥10 |
| Score | 0 | 25 | 50 | 75 | 100 | |
| CIR (cumulated incidence ratio) | Value | <1 | 1–1.9 | 2–5.9 | 6–19.9 | ≥20 |
| Score | 0 | 25 | 50 | 75 | 100 | |
| ERI (epidemic risk index) | Value | 0 | 0.1–0.2 | 0.3–0.4 | ≥0.5 | |
| Score | 0 | 33 | 66 | 100 | ||
Abbreviations: CBR, case burden ratio; CIR, cumulative incidence ratio; ERI, epidemic risk index.
Figure 2.Progress of group A meningococcal polysaccharide–tetanus toxoid conjugate vaccine (PsA-TT) conjugate vaccine introduction and District Prioritization Tool (DPT) evaluations in Africa, 2010–2016.
Metadata and Outcome of District Prioritization Tool Evaluations by Chronological Order, Africa, July 2011–December 2014
| Country | Year of DPT Evaluation | Scale of Primary Evaluation | Scale of Campaign Implementation | Surveillance Years Included | Estimated Target Population at the Time of DPT Evaluation | Proposed No. of Phases for PsA-TT Introduction |
|---|---|---|---|---|---|---|
| Nigeriaa | 2011 | LGA (353) | State (26) | 2007–2011 | 50 547 012 | 3 |
| Chada | 2011 | District (61) | Delegation (20) | 2006–2011 | 5 113 785 | 2 |
| Cameroona | 2011 | District (179) | Region (10) | 2006–2011 | 6 012 450 | 2 |
| Sudan | 2011 | Locality (156) | State (15) | 2005–2011 | 24 787 935 | 2 |
| Ethiopia | 2012 | Zone (97) | Region (11) | 2004–2011 | 58 427 373 | 3 |
| DRCb | 2012 | Zone (515) | District (42) or province (11) | 2005–2012 | NA | NA |
| South Sudan | 2013 | County (80) | State (10) | 2010–2012 | 5 694 045 | 3 |
| Côte d'Ivoire | 2013 | District (25) | Region (7) | 2005–2013 | 4 314 015 | 2 |
| Guinea | 2013 | Prefecture (38) | Region (8) | 2008–2013 | 3 571 869 | 2 |
| Togo | 2013 | District (35) | Region (6) | 2005–2013 | 2 677 790 | 1 |
| Mauritania | 2013 | Moughataa (55) | Region (13) | 2007–2013 | 1 468 767 | 3 |
| Uganda | 2014 | District (112) | Region (4) | 2004–2014 | 7 581 340 | 1 |
| Kenya | 2014 | District (158) | District (158) | 2010–2014 | 1 578 922 | 1 |
Data provided in parentheses indicate the number of units included in the analysis.
Abbreviations: DPT, District Prioritization Tool; DRC, Democratic Republic of Congo; LGA, local government area; NA, not applicable; PsA-TT, group A meningococcal polysaccharide–tetanus toxoid conjugate vaccine.
a Pilot implementation.
b Available data were not sufficient to provide final results.
Figure 3.Example of District Prioritization Tool quantitative outputs submitted to local expert review. A, District-level risk category in Côte d'Ivoire using 2005–2013 surveillance data. B, State-level priority phase in Sudan using 2005–2011 surveillance data. (Ability to conduct the campaigns performance flags were deliberately omitted for the sake of clarity.)